Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Price: $28.54 -1.79%
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Wells Fargo analyst Derek Archila upgraded Viridian Therapeutic (NASDAQ: VRDN) from Equal Weight to Overweight with a price target of $31.00.
For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.
Shares of Viridian Therapeutic closed at $17.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CIMB Upgrades TIME dotCom Berhad (TDC:MK) to Buy
- Dutch Bros Inc. (BROS) PT Lowered to $55 at DA Davidson
- American International Group (AIG) PT Raised to $89 at Mizuho
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
